- Trials with a EudraCT protocol (251)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
251 result(s) found for: Atrial function.
Displaying page 1 of 13.
EudraCT Number: 2009-013228-21 | Sponsor Protocol Number: | Start Date*: 2010-07-06 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: Prevention of atrial oxidative stress and electrical remodelling in patients undergoing cardiac surgery: randomised placebo-controlled trial of perioperative high-dose atorvastatin | |||||||||||||
Medical condition: POST-OPERATIVE ATRIAL FIBRILLATION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000797-30 | Sponsor Protocol Number: SPI-IIT-002 | Start Date*: 2013-10-08 | |||||||||||||||||||||
Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital | |||||||||||||||||||||||
Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation | |||||||||||||||||||||||
Medical condition: Paroxysmal and persistent atrial fibrillation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001382-15 | Sponsor Protocol Number: ATI-2042-CLN-205 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:ARYx Therapeutics | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities | |||||||||||||
Medical condition: The trial is to investigate the efficacy of the new drug ATI-2042 to reduce the atrial tachyarrhythmia burden in patients with paroxysmal atrial fabrilation. ATI-2042 is designed to act like Amioda... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000503-40 | Sponsor Protocol Number: GE IDE No. A01611 | Start Date*: 2011-04-12 | |||||||||||
Sponsor Name:Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen | |||||||||||||
Full Title: DABI-ADP-1: IMPACT OF DABIGATRAN AND PHENPROCOUMON ON ADP INDUCED PLATELET AGGREGATION IN PATIENTS WITH ATRIAL FIBRILLATION | |||||||||||||
Medical condition: Patients with atrial fibrillation and an indication for oral anticoagulation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002442-45 | Sponsor Protocol Number: AXAFA-AFNET5 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)] | ||||||||||||||||||||||||||||
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy. | ||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation catheter ablation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002755-94 | Sponsor Protocol Number: CV185-391 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: MicroRNAs and target genes modulation in subjects with atrial fibrillation treated with apixaban or warfarin | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002752-20 | Sponsor Protocol Number: LAN_POAF_01 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: A prospective, randomized, double- blind, placebo- controlled study to evaluate the efficacy of Landiolol hydrochloride for prevention of atrial fibrillation in patients undergoing cardiac surgery | |||||||||||||
Medical condition: Perioperative atrial fibrillation (POAF) is the most common arryhthmia after cardiac surgery with incidences ranging from 20% to 40%, depending on various patient's risk factors and the type of sur... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000058-21 | Sponsor Protocol Number: CLOSURE-AF-DZHK16 | Start Date*: 2018-03-01 | |||||||||||
Sponsor Name:Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin | |||||||||||||
Full Title: Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial | |||||||||||||
Medical condition: Atrial Fibrillation with high risk of stroke and bleeding | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019247-19 | Sponsor Protocol Number: DRONE_C_04629 | Start Date*: 2010-10-12 | |||||||||||
Sponsor Name:sanofi aventis groupe | |||||||||||||
Full Title: A Randomized, international, multi-center, open-label study to document pharmacokinetics and optimal timing of initiation of dronedarone TreatmEnt following long-term aMIodarone in patients with pa... | |||||||||||||
Medical condition: Paroxysmal or persistent atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) FR (Completed) DE (Completed) DK (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005437-38 | Sponsor Protocol Number: D1250C00008 | Start Date*: 2007-03-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of... | |||||||||||||
Medical condition: Paroxysmal, persistent or permanent nonvalvular atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016818-24 | Sponsor Protocol Number: DRONE_C_03668 | Start Date*: 2010-08-26 | |||||||||||
Sponsor Name:sanofi aventis | |||||||||||||
Full Title: A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSi... | |||||||||||||
Medical condition: Persistant atrial fibrillation requiring conversion of AF | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) FI (Completed) DE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004399-68 | Sponsor Protocol Number: 1925-201-008 | Start Date*: 2019-03-29 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN 151607) Injections into the Epicardial F... | |||||||||||||
Medical condition: Post-operative atrial fibrillation (POAF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) AT (Completed) SE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005043-13 | Sponsor Protocol Number: RG_14-187 | Start Date*: 2016-08-11 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Evaluating different rate control therapies in permanent atrial fibrillation: A prospective, randomised, open-label, blinded endpoint study comparing digoxin and beta-blockers as initial rate contr... | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011291-29 | Sponsor Protocol Number: RACE 3 | Start Date*: 2011-08-16 | |||||||||||
Sponsor Name:Interuniversity Cardiology Institute of the Netherlands (ICIN) | |||||||||||||
Full Title: Routine versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3 | |||||||||||||
Medical condition: atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003702-33 | Sponsor Protocol Number: RG_14-150 | Start Date*: 2015-01-23 | |||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||
Full Title: IMPRESS-AF: IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation | |||||||||||||||||||||||
Medical condition: Atrial fibrillation with preserved left ventricular systolic function and normal levels of the brain natriuretic peptide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002338-35 | Sponsor Protocol Number: 144 | Start Date*: 2013-05-06 | |||||||||||
Sponsor Name:Biosense Webster, Inc. | |||||||||||||
Full Title: ATrial FibrillaTion ProgrESsion Trial (ATTEST Trial) | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003100-13 | Sponsor Protocol Number: KKSH-154 | Start Date*: 2020-08-03 | |||||||||||
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | |||||||||||||
Full Title: Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention | |||||||||||||
Medical condition: Nonvalvular Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001795-30 | Sponsor Protocol Number: DU176b-C-E314 | Start Date*: 2016-11-11 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance | |||||||||||||
Medical condition: Non-Valvular Atrial Fibrillation (NVAF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) SK (Completed) DK (Completed) HU (Completed) ES (Completed) BE (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002532-12 | Sponsor Protocol Number: IDE:G050233 | Start Date*: 2011-10-27 | |||||||||||
Sponsor Name:MAYO CLINIC | |||||||||||||
Full Title: Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA) | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000263-92 | Sponsor Protocol Number: 17-251 | Start Date*: 2018-05-28 | |||||||||||
Sponsor Name:CHU CAEN | |||||||||||||
Full Title: Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: a multicenter randomized, double-blind study | |||||||||||||
Medical condition: Patients > 18 years referred for elective cardiac bypass graft (CABG) surgery ± aortic valve replacement (AVR) without any systolic heart failure or any mitral surgery associated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
